AR092400A1 - Formulaciones de anticuerpos y proteinas de alta concentracion - Google Patents
Formulaciones de anticuerpos y proteinas de alta concentracionInfo
- Publication number
- AR092400A1 AR092400A1 ARP130103099A ARP130103099A AR092400A1 AR 092400 A1 AR092400 A1 AR 092400A1 AR P130103099 A ARP130103099 A AR P130103099A AR P130103099 A ARP130103099 A AR P130103099A AR 092400 A1 AR092400 A1 AR 092400A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- antibody
- protein
- antibody formulation
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 17
- 108090000623 proteins and genes Proteins 0.000 title abstract 11
- 102000004169 proteins and genes Human genes 0.000 title abstract 11
- 238000009472 formulation Methods 0.000 abstract 16
- 235000018102 proteins Nutrition 0.000 abstract 10
- 229930006000 Sucrose Natural products 0.000 abstract 5
- 239000005720 sucrose Substances 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 4
- 239000004475 Arginine Substances 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 229930182817 methionine Natural products 0.000 abstract 3
- 239000002736 nonionic surfactant Substances 0.000 abstract 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 3
- 229920000053 polysorbate 80 Polymers 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000008121 dextrose Substances 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000185 sucrose group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan formulaciones de alta concentración sin sal de anticuerpos y otras proteínas que son sustancialmente isosmóticas y de baja viscosidad. También se proporcionan procedimientos para el tratamiento de enfermedades usando las formulaciones divulgadas. Reivindicación 1: Una formulación de proteína o anticuerpo sin sal, que comprende: a) 10 mM a 30 mM de histidina; b) 50 ppm a 200 ppm de un tensioactivo no iónico; c) 88 mM a 292 mM de un azúcar o alcohol de azúcar seleccionado entre manitol, dextrosa, glucosa, trehalosa y sacarosa; d) 0 mM a 50 mM de arginina; e) 0 mM a 50 mM de lisina; f) 0 mM a 133 mM de glicina o alanina; g) 0 mM a 10 mM de metionina; y h) 20 mg/ml a 150 mg/ml de una proteína o un anticuerpo; en la que dicha formulación de proteína o anticuerpo tiene un pH que varía de pH 4,0 a pH 6,0 y en la que dicha formulación de proteína no contiene sustancialmente sal inorgánica. Reivindicación 4: La formulación de proteína o anticuerpo sin sal de cualquiera de la reivindicación 1, en la que dicho tensioactivo no iónico es un polisorbato seleccionado entre polisorbato 20 y polisorbato 80. Reivindicación 5: La formulación de proteína o anticuerpo sin sal de la reivindicación 1, en la que dicho azúcar es sacarosa. Reivindicación 7: La formulación de proteína o anticuerpo sin sal de la reivindicación 1, que comprende: a) 30 mM de histidina, b) 100 ppm de polisorbato 80, c) 292 mM de sacarosa, y d) 20 mg/ml de proteína o anticuerpo; en la que dicha formulación de proteína o anticuerpo tiene un pH que varía de pH 5,0 a pH 6,0. Reivindicación 17: Una formulación de anticuerpo anti-TFPI sin sal, que comprende: a) 10 mM a 30 mM de histidina, b) 50 ppm a 200 ppm de un tensioactivo no iónico, c) 88 mM a 292 mM de un azúcar o alcohol de azúcar seleccionado entre manitol, dextrosa, glucosa, trehalosa y sacarosa, d) 0 mM a 50 mM de arginina, e) 0 mM a 50 mM de lisina, f) 0 mM a 133 mM de glicina o alanita, g) 0 mM a 10 mM de metionina, y h) 20 mg/ml a 150 mg/ml de anticuerpo anti-TFPI; en la que dicha formulación de anticuerpo anti-TFPI tiene un pH de pH 4,0 a pH 6,0 y en la que dicha formulación de anticuerpo anti-TFPI no contiene sustancialmente sal inorgánica. Reivindicación 22: La formulación de anticuerpo anti-TFPI sin sal de la reivindicación 17, que comprende: a) 10 mM de histidina, b) 75 ppm de Tween 80, c) 234 mM de sacarosa, d) 30 mM de arginina, y e) 10 mM de metionina, y f) 100 mg/ml de anticuerpo anti-TFPI; en la que dicha formulación de anticuerpo anti-TFPI tiene un pH de 5,5. Reivindicación 23: La formulación de anticuerpo anti-TFPI sin sal de la reivindicación 17, en la que dicho anticuerpo anti-TFPI es un anticuerpo monoclonal lgG₂ humano. Reivindicación 24: La formulación de anticuerpo anti-TFPI sin sal de la reivindicación 17, en la que dicho anticuerpo monoclonal lgG₂ humano comprende una cadena ligera que comprende la secuencia de aminoácidos de SEC ID Nº 1 y una cadena pesada que comprende la secuencia de aminoácidos de SEC ID Nº 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/601,598 US8613919B1 (en) | 2012-08-31 | 2012-08-31 | High concentration antibody and protein formulations |
| US13/843,780 US9592297B2 (en) | 2012-08-31 | 2013-03-15 | Antibody and protein formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092400A1 true AR092400A1 (es) | 2015-04-22 |
Family
ID=49162239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103085A AR092388A1 (es) | 2012-08-31 | 2013-08-29 | Formulaciones de anticuerpo y proteina |
| ARP130103099A AR092400A1 (es) | 2012-08-31 | 2013-08-30 | Formulaciones de anticuerpos y proteinas de alta concentracion |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103085A AR092388A1 (es) | 2012-08-31 | 2013-08-29 | Formulaciones de anticuerpo y proteina |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9592297B2 (es) |
| EP (3) | EP3117837B1 (es) |
| JP (3) | JP6462567B2 (es) |
| CN (2) | CN114392353A (es) |
| AR (2) | AR092388A1 (es) |
| AU (3) | AU2013308902B2 (es) |
| BR (1) | BR112015003838A2 (es) |
| CA (2) | CA3129277A1 (es) |
| CY (1) | CY1121989T1 (es) |
| DK (1) | DK3117837T3 (es) |
| ES (1) | ES2741575T3 (es) |
| HK (1) | HK1210794A1 (es) |
| HR (1) | HRP20191299T1 (es) |
| HU (1) | HUE045652T2 (es) |
| IL (6) | IL286784B (es) |
| LT (1) | LT3117837T (es) |
| MX (2) | MX369653B (es) |
| PL (1) | PL3117837T3 (es) |
| PT (1) | PT3117837T (es) |
| RS (1) | RS59221B1 (es) |
| RU (2) | RU2678097C2 (es) |
| SG (2) | SG10201708215YA (es) |
| SI (1) | SI3117837T1 (es) |
| TW (4) | TW201927338A (es) |
| UY (1) | UY34995A (es) |
| WO (1) | WO2014036071A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2542257T3 (en) | 2010-03-01 | 2017-10-16 | Bayer Healthcare Llc | OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI) |
| WO2012135671A2 (en) * | 2011-04-01 | 2012-10-04 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| AT512589B1 (de) * | 2012-03-12 | 2014-06-15 | Zizala Lichtsysteme Gmbh | Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| CN110496099B (zh) | 2013-09-11 | 2022-06-21 | 伊戈尔生物药品股份有限公司 | 包含粘度降低剂的液体蛋白质制剂 |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2016054259A1 (en) | 2014-10-01 | 2016-04-07 | Arsia Therapeutics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN113956361A (zh) | 2014-10-01 | 2022-01-21 | 免疫医疗有限公司 | 替格瑞洛的抗体及其使用方法 |
| CN107922506B (zh) | 2015-08-19 | 2021-11-09 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| DK3769781T5 (da) | 2015-08-19 | 2024-08-19 | Astrazeneca Ab | Stabil anti-ifnar1-formulering |
| AU2016329034B2 (en) * | 2015-09-22 | 2019-05-23 | Pfizer Inc. | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
| WO2017180594A1 (en) * | 2016-04-13 | 2017-10-19 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| PT3479819T (pt) | 2016-06-30 | 2024-04-15 | Celltrion Inc | Preparação farmacêutica líquida estável |
| US10279048B2 (en) | 2016-07-13 | 2019-05-07 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| RU2744630C2 (ru) | 2016-09-16 | 2021-03-12 | Льюкокэар Аг | Новый способ стабилизации биофармацевтического лекарственного продукта при производстве |
| MY197200A (en) * | 2016-12-23 | 2023-05-31 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
| CN112004827A (zh) * | 2018-03-23 | 2020-11-27 | 艾伯维德国有限责任两合公司 | 稳定的水性抗tau抗体调配物 |
| BR112020022610A2 (pt) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | proteína de fusão de receptor de vegf de alta concentração que contém formulações |
| SG11202100028PA (en) * | 2018-07-05 | 2021-01-28 | Bayer Ag | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| CN113056482A (zh) * | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN111346225A (zh) * | 2018-12-21 | 2020-06-30 | 上海张江生物技术有限公司 | 含有蛋白质的药物制剂 |
| BR112021015034A2 (pt) * | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
| EP3962942A1 (en) * | 2019-05-01 | 2022-03-09 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
| US20230035617A1 (en) * | 2019-11-13 | 2023-02-02 | Pfizer Inc. | Stable aqueous anti-tfpi antibody formulation |
| TW202404640A (zh) * | 2022-07-27 | 2024-02-01 | 美商維埃拉生物股份有限公司 | 包含免疫球蛋白樣轉錄本７（ｉｌｔ７）結合蛋白之調配物 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4075193A (en) | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
| US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| ES2044941T5 (es) | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | Estabilizador de hormonas promotoras del crecimiento. |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US4912861A (en) * | 1988-04-11 | 1990-04-03 | Huang Ing Chung | Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods |
| US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| JPH03504605A (ja) | 1988-05-27 | 1991-10-09 | セントカー・インコーポレーテツド | 抗体産生物の凍結乾燥した配合物 |
| EP0465513A1 (en) | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| EP0686045B1 (en) | 1993-02-23 | 2000-11-15 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO1997004801A1 (en) | 1995-07-27 | 1997-02-13 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
| AU2150497A (en) | 1996-01-25 | 1997-08-20 | Schering Aktiengesellschaft | Improved concentrated injection and infusion solutions for intravenous adminis tration |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| CA2302708A1 (en) | 1997-08-21 | 1999-03-04 | Siemens Aktiengesellschaft | Method for transmitting user data that can be allocated to different applications |
| GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| HUP0203133A3 (en) | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| JP4683810B2 (ja) | 2000-02-29 | 2011-05-18 | 中外製薬株式会社 | 長期安定化製剤 |
| AU2001251336B2 (en) | 2000-04-07 | 2006-09-14 | Signal Coordinating Therapy, Inc. | Methods and compositions for treating neoplasms |
| AU2001276737A1 (en) | 2000-08-04 | 2002-02-18 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| KR20030027077A (ko) | 2000-09-01 | 2003-04-03 | 쥬가이 세이야쿠 가부시키가이샤 | 장기 안정화 용액 제제 |
| JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| US8372798B2 (en) | 2001-10-16 | 2013-02-12 | Endo Pharmaceuticals Colorado, Inc. | High-concentration protein formulations and method of manufacture |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| WO2003062375A2 (en) | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| NZ534542A (en) | 2002-02-14 | 2006-08-31 | Chugai Pharmaceutical Co Ltd | Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| CN1671741A (zh) | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| JP2006502116A (ja) | 2002-07-12 | 2006-01-19 | メダレックス， インク． | タンパク質の酸化分解を防ぐ方法及び組成物 |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| DK1556083T3 (da) | 2002-10-08 | 2011-04-04 | Rinat Neuroscience Corp | Fremgangsmåde til behandling af post-operative smerter ved indgivelse af en antistof mod nervevækstfaktor og sammensætning indeholdende samme |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| KR101250818B1 (ko) | 2002-12-24 | 2013-04-15 | 리나트 뉴로사이언스 코프. | 항-ｎｇｆ 항체 및 그것을 이용하는 방법 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CA2519408C (en) * | 2003-04-04 | 2011-01-18 | Genentech, Inc. | High concentration antibody and protein formulations |
| SG10201404744RA (en) | 2003-07-15 | 2014-10-30 | Medarex Llc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| JP4219932B2 (ja) | 2003-10-01 | 2009-02-04 | 協和発酵キリン株式会社 | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| EP1755677A4 (en) | 2004-06-14 | 2009-11-25 | Medimmune Vaccines Inc | HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TW200638943A (en) | 2005-01-28 | 2006-11-16 | Wyeth Corp | Stabilized liquid polypeptide formulations |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CA2600601A1 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-m-csf antibody compositions having reduced levels of endotoxin |
| AU2006220829C1 (en) | 2005-03-08 | 2024-02-01 | Pfizer Products Inc. | Anti-CTLA-4 antibody compositions |
| KR101280273B1 (ko) | 2005-04-18 | 2013-07-15 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형 |
| AU2006261920A1 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
| WO2007003936A1 (en) | 2005-07-02 | 2007-01-11 | Arecor Limited | Stable aqueous systems comprising proteins |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| EP1916997B1 (en) | 2005-08-05 | 2018-04-18 | Amgen Inc. | Stable aqueous protein pharmaceutical formulations and their preparation |
| WO2007056847A1 (en) | 2005-11-21 | 2007-05-24 | Sanofi Pasteur Limited | Stabilizing formulations for recombinant viruses |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
| US20100158925A1 (en) | 2006-06-14 | 2010-06-24 | Meera Agarkhed | Lyophilized formulations of anti-egfr antibodies |
| US8206709B2 (en) | 2006-06-30 | 2012-06-26 | Novo Nordisk A/S | Anti-NKG2A antibodies and uses thereof |
| CN101522219A (zh) | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
| TW200831133A (en) * | 2006-12-11 | 2008-08-01 | Hoffmann La Roche | Mab Abeta lyophylized formulation |
| EP2703007A1 (en) | 2007-03-30 | 2014-03-05 | MedImmune, LLC | Antibodies with decreased deamidation profiles |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| TWI614028B (zh) | 2007-06-14 | 2018-02-11 | 百健Ｍａ公司 | 抗體調配物 |
| US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | タンパク質製剤 |
| CN110698561A (zh) | 2007-12-14 | 2020-01-17 | 诺沃—诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
| PT2234600E (pt) | 2007-12-21 | 2014-09-25 | Hoffmann La Roche | Formulação de anticorpos |
| NZ586303A (en) | 2007-12-28 | 2012-03-30 | Bioinvent Int Ab | Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis |
| EP2254911B1 (en) | 2008-02-20 | 2015-11-25 | Novo Nordisk A/S | Humanized anti-c5ar antibodies |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| MX2010013565A (es) | 2008-06-30 | 2011-01-14 | Novo Nordisk As | Anticuerpos de interleucina-20 anti-humanos. |
| UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| MX2011003013A (es) | 2008-09-19 | 2011-04-11 | Pfizer | Formulacion liquida estable de anticuerpos. |
| EP2350649A4 (en) * | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| RU2562114C2 (ru) | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Антитела против ингибитора метаболического пути тканевого фактора |
| TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
| US20120114646A1 (en) | 2009-06-18 | 2012-05-10 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| LT2805731T (lt) | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stabilios polipeptidų kompozicijos ir jų panaudojimas |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| DK2542257T3 (en) | 2010-03-01 | 2017-10-16 | Bayer Healthcare Llc | OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI) |
| WO2011108452A1 (ja) * | 2010-03-02 | 2011-09-09 | Jnc株式会社 | 還元反応器 |
| ES2983470T3 (es) * | 2010-03-19 | 2024-10-23 | Takeda Pharmaceuticals Co | Inhibidores del TFPI y métodos de uso |
| AU2011257219B2 (en) | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| BR112013008366B1 (pt) * | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| WO2012135671A2 (en) | 2011-04-01 | 2012-10-04 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2013
- 2013-03-15 US US13/843,780 patent/US9592297B2/en active Active
- 2013-08-28 HU HUE16180643A patent/HUE045652T2/hu unknown
- 2013-08-28 SG SG10201708215YA patent/SG10201708215YA/en unknown
- 2013-08-28 PT PT16180643T patent/PT3117837T/pt unknown
- 2013-08-28 US US14/421,607 patent/US20150209431A1/en not_active Abandoned
- 2013-08-28 EP EP16180643.5A patent/EP3117837B1/en active Active
- 2013-08-28 CA CA3129277A patent/CA3129277A1/en active Pending
- 2013-08-28 EP EP13760179.5A patent/EP2890718A1/en not_active Withdrawn
- 2013-08-28 SG SG11201501116RA patent/SG11201501116RA/en unknown
- 2013-08-28 ES ES16180643T patent/ES2741575T3/es active Active
- 2013-08-28 CN CN202111330122.3A patent/CN114392353A/zh active Pending
- 2013-08-28 RU RU2015111341A patent/RU2678097C2/ru not_active IP Right Cessation
- 2013-08-28 IL IL286784A patent/IL286784B/en unknown
- 2013-08-28 WO PCT/US2013/056970 patent/WO2014036071A1/en active Application Filing
- 2013-08-28 DK DK16180643.5T patent/DK3117837T3/da active
- 2013-08-28 IL IL294567A patent/IL294567A/en unknown
- 2013-08-28 EP EP19175217.9A patent/EP3590536A1/en not_active Ceased
- 2013-08-28 CA CA2883095A patent/CA2883095C/en active Active
- 2013-08-28 PL PL16180643T patent/PL3117837T3/pl unknown
- 2013-08-28 LT LTEP16180643.5T patent/LT3117837T/lt unknown
- 2013-08-28 RU RU2019100887A patent/RU2019100887A/ru not_active Application Discontinuation
- 2013-08-28 RS RSP20190976 patent/RS59221B1/sr unknown
- 2013-08-28 JP JP2015529977A patent/JP6462567B2/ja not_active Expired - Fee Related
- 2013-08-28 BR BR112015003838A patent/BR112015003838A2/pt not_active Application Discontinuation
- 2013-08-28 CN CN201380051319.0A patent/CN104684933B/zh not_active Expired - Fee Related
- 2013-08-28 AU AU2013308902A patent/AU2013308902B2/en not_active Ceased
- 2013-08-28 SI SI201331538T patent/SI3117837T1/sl unknown
- 2013-08-28 MX MX2015002411A patent/MX369653B/es active IP Right Grant
- 2013-08-29 AR ARP130103085A patent/AR092388A1/es unknown
- 2013-08-29 UY UY0001034995A patent/UY34995A/es not_active Application Discontinuation
- 2013-08-30 TW TW108113538A patent/TW201927338A/zh unknown
- 2013-08-30 TW TW106131685A patent/TW201825116A/zh unknown
- 2013-08-30 TW TW102131180A patent/TWI609697B/zh not_active IP Right Cessation
- 2013-08-30 TW TW102131326A patent/TW201414496A/zh unknown
- 2013-08-30 AR ARP130103099A patent/AR092400A1/es unknown
- 2013-12-16 US US14/107,658 patent/US20140105892A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,408 patent/US9849181B2/en active Active
-
2015
- 2015-02-11 IL IL237188A patent/IL237188A0/en unknown
- 2015-02-24 MX MX2019013670A patent/MX2019013670A/es unknown
- 2015-11-27 HK HK15111675.2A patent/HK1210794A1/xx unknown
-
2017
- 2017-08-16 US US15/679,053 patent/US20180055940A1/en not_active Abandoned
- 2017-10-18 US US15/787,610 patent/US20180028669A1/en not_active Abandoned
-
2018
- 2018-05-11 AU AU2018203320A patent/AU2018203320B2/en not_active Expired - Fee Related
- 2018-12-17 JP JP2018235273A patent/JP2019048886A/ja active Pending
-
2019
- 2019-04-07 IL IL265865A patent/IL265865A/en unknown
- 2019-04-07 IL IL265864A patent/IL265864B/en active IP Right Grant
- 2019-07-18 HR HRP20191299TT patent/HRP20191299T1/hr unknown
- 2019-08-16 CY CY20191100881T patent/CY1121989T1/el unknown
-
2020
- 2020-01-08 AU AU2020200134A patent/AU2020200134A1/en not_active Abandoned
- 2020-11-11 US US17/095,102 patent/US20230190637A9/en not_active Abandoned
- 2020-12-06 IL IL279237A patent/IL279237A/en unknown
-
2021
- 2021-01-13 JP JP2021003390A patent/JP2021059602A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092400A1 (es) | Formulaciones de anticuerpos y proteinas de alta concentracion | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| PE20181889A1 (es) | Preparaciones que contienen anticuerpos | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| AR080428A1 (es) | Formulaciones liquidas estabilizadas contentivas de anticuerpos | |
| AR104198A2 (es) | Formulaciones de proteínas y anticuerpos de alta concentración | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| EA201590758A1 (ru) | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| ECSP088962A (es) | Nuevos herbicidas | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| AR090272A1 (es) | FORMULACION DE ANTICUERPOS Ab | |
| AR092050A1 (es) | Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas | |
| PE20220337A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| RU2015137685A (ru) | Композиции антитела в низкой концентрации | |
| PE20091783A1 (es) | Anticuerpos anti-factor d humanizados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |